摘要
沐舒坦作为一种粘液溶解剂,临床应用广泛。然而,沐舒坦的临床应用剂量的选择跨度较大,疗程长短也存在差异,还未能达成共识。其疗效与剂量的相关性有待于临床实验探究。随着遗传药理学和药物基因组学的兴起,研究沐舒坦是否存在遗传和基因组因素的影响,可能为其临床应用剂量的选择及个体化用药开拓新的视野。
Ambroxol as a mucolytic agent,is applied extensively in clinic nowadays.However,the range of its dose selection is large,the duration is also different,and it has not been reached an agreement yet.The relativity of its efficacy and dose needs further research in clinical trials.With the spring up of pharmacogenetics and pharmacogenomics,the question that whether there is a genetic and genomic factors in mucosolvan is not clear,and the solution of this problem may open up a new prospect of its individualized medication.
出处
《实用药物与临床》
CAS
2012年第5期301-302,共2页
Practical Pharmacy and Clinical Remedies
关键词
沐舒坦
剂量
药物基因组学
Ambroxol
Perioperative period
Pharmacogenomics
